Pirfenex
Pirfenex Price range: $ 37,00 through $ 404,00
Back to products
Plendil
Plendil Price range: $ 13,00 through $ 267,00

Placentrex

Price range: $ 54,00 through $ 149,00

Placentrex is a specialized therapeutic agent derived from purified human placental extract, recognized for its powerful regenerative and anti-inflammatory properties. This medication effectively accelerates the healing process of chronic wounds, surgical incisions, and various types of skin ulcers. By stimulating cellular repair and enhancing tissue metabolism, the formula helps the body restore damaged areas more efficiently. It is also frequently utilized to manage pelvic inflammatory disease and other conditions where promoting tissue health is essential. This versatile treatment offers a reliable solution for those seeking to support their body’s natural recovery and skin rejuvenation processes.

SKU: Placentrex Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Placentrex belongs to a biological class of preparations containing derived human placental extract. The agent is historically prescribed in select international medical practices for promoting tissue regeneration, managing chronic non-healing wounds, and reducing localized tissue inflammation.

Because regulatory status varies significantly across international jurisdictions, any administration of human placenta extract must be dispensed in accordance with applicable federal and state regulations under qualified clinical supervision.

Parameter Details
Active ingredient Human Placenta Extract
Primary purpose Tissue repair and wound healing support
Dosage form Topical gel / Injectable solution
Route of administration Topical / Intramuscular
Prescription status Dispensed in accordance with applicable federal and state regulations
Storage Store below 25°C (77°F), protect from direct light

Product Summary and Clinical Overview

How the drug works

Human placenta extract contains a complex biological mixture of active constituents, including nucleotides, essential amino acids, small peptides, biological vitamins, and endogenous growth factors such as fibroblast growth factor and transforming growth factor. These bioactive compounds act cellularly to stimulate tissue cell proliferation, enhance localized cellular respiration, and encourage angiogenesis–the formation of new microvascular blood vessel networks–in damaged dermal tissues. Within mucosal and cutaneous surfaces, the extract supports collagen synthesis and extracellular matrix restructuring. This biological activity accelerates epithelialization and facilitates secondary intention wound healing.

Main uses

Placentrex is primarily indicated for assisting wound closure in chronic, non-healing cutaneous lesions, such as diabetic foot ulcers, venous stasis ulcers, burn recovery, and dehisced surgical wounds. In certain non-US clinical settings, the extract has also been evaluated off-label for gynecological conditions such as pelvic inflammatory disease and chronic inflammatory periodontitis. Note that off-label applications lack official approval from the U.S. Food and Drug Administration (FDA) and require rigorous individualized clinical assessment before consideration. Therapeutic application is restricted to clinical scenarios where conventional wound care requires supplementary biological tissue support.

Dosing schedule and pharmacokinetics

Dosing schedule: The administration protocol depends on the specific pharmaceutical formulation (topical gel vs. parenteral solution) and the underlying clinical goal. Topical gel is typically applied in a thin layer to clean, debrided wound surfaces once or twice daily, under the direct guidance of a healthcare professional. Injectable formulations, where authorized, are administered via deep intramuscular injection by trained medical personnel. Exact dosing regimens are determined individually based on lesion size, clinical progress, and patient tolerance. Patients must not alter application frequency or duration without medical instruction.

How it’s absorbed and eliminated: Detailed pharmacokinetic parameters for human placenta extract, such as specific systemic bio-availability, volume of distribution, and quantitative metabolic elimination half-life, are not fully defined in standard scientific literature due to the complex multi-component biological matrix of the product. Topical administration results primarily in localized tissue penetration with minimal systemic absorption across intact dermal barriers. Systemically absorbed peptide fragments undergo catabolism by endogenous proteolytic enzymes into native amino acids, which are subsequently eliminated through metabolic pathways.

Safety, adverse reactions, and interactions

Compatibility with other medicines: Dedicated systemic drug interaction studies for placenta extract are limited. Co-application of topical Placentrex gel with other local dermatological formulations, strong proteolytic enzymes, or heavy metal-containing topical antiseptics may alter protein stability or diminish the biological activity of contained growth factors. Concomitant systemic administration of immunosuppressants or high-dose corticosteroids may theoretically modify local tissue repair responses. Patients should inform their physician or pharmacist of all concurrent medications, topical treatments, and supplements.

Adverse reactions: Side effects associated with Placentrex application are predominantly localized to the site of administration. Frequently observed reactions include local cutaneous erythema, mild burning or stinging sensations, contact dermatitis, pruritus, or transient local hyperpigmentation. Parenteral administration may occasionally cause localized injection-site discomfort or mild, self-limiting systemic fever. Any severe allergic skin reaction, spreading inflammation, or systemic signs of hypersensitivity require immediate discontinuation of the agent and prompt clinical evaluation.

Important precautions: Placentrex is contraindicated in individuals with a known history of severe hypersensitivity to biological human-derived tissue products. Although pharmaceutical manufacturing standards incorporate donor screening and validated viral clearance steps, inherent biological risks require ongoing clinical vigilance. The preparation should not be applied to actively infected, purulent wounds without concurrent appropriate antimicrobial therapy. Patients with severe peripheral arterial occlusive disease require specialized monitoring during wound healing regimens.

Frequently Asked Questions and Storage

What you may notice early on: Patients initiating topical gel therapy may observe mild localized warmth or brief tingling immediately after application. The formation of healthy granulation tissue typically progresses over several days to weeks rather than manifesting as an immediate physical change. Clinical monitoring of wound edges for swelling, abnormal discharge, or skin discoloration is essential during the early phase of treatment.

Pregnancy, breastfeeding, and other groups: Adequate and well-controlled clinical safety studies regarding human placenta extract in pregnant or lactating women are unavailable. Consequently, use during pregnancy or breastfeeding is generally not recommended unless explicitly deemed necessary by a prescribing clinician following a formal risk-benefit evaluation. Safety and efficacy profiles in pediatric patients have not been formally established. Elderly patients should undergo evaluation for vascular and renal function prior to starting therapy.

Storage and expiration: Store Placentrex in its original container at controlled room temperature below 25°C (77°F). Protect the product from exposure to direct sunlight, high humidity, and excessive heat. Do not freeze, as freezing temperatures can denature active biological proteins and growth factors. Keep the tube or container tightly closed when not in use. Discard any unused product past the expiration date printed on the outer packaging.

What to ask your provider: Before starting therapy, patients are advised to discuss the following questions with their physician or pharmacist: Is Placentrex appropriate for my specific wound severity? Are there alternative FDA-approved treatments available for my condition? How often should my wound dressing be updated? What specific signs signal an adverse reaction requiring immediate medical care?

Common questions:

How long does it typically take to see measurable wound healing with Placentrex?

Biological tissue repair is a gradual process. Early evidence of granulation tissue formation and wound edge contraction is generally evaluated by a clinician over 1 to 4 weeks, depending on wound depth, local blood supply, and adherence to complete wound care measures.

Can Placentrex gel be applied directly to infected wounds?

No, biological extract preparations should not be applied directly to infected or purulent lesions without concurrent appropriate antimicrobial treatment, as applying topical gels over untreated infections can exacerbate tissue complications.

What should I do if a topical dose of Placentrex is missed?

If an application is missed, apply the gel as soon as remembered, unless it is nearly time for the next scheduled application. Do not apply extra gel or double the dose to compensate for a missed application.

Is Placentrex officially approved by the FDA in the United States?

Placentrex is not an FDA-approved drug in the United States. Its legal status varies by international jurisdiction, and within the US market, it must be handled in accordance with applicable federal and state regulatory requirements under medical supervision.

What steps should be taken if severe localized skin irritation develops?

If significant redness, swelling, severe burning, or skin rash develops following application, gently cleanse the area with mild soap and water, discontinue further application, and seek immediate evaluation from a licensed healthcare provider.

This text is for informational purposes only and does not constitute individual medical advice.

In accordance with FDA guidelines, unapproved foreign biological products require clinical supervision and evaluation by a licensed healthcare provider.

Additional information
Dosage

10%+0.25% 20g

Package

3 tubes

,

4 tubes

,

5 tubes

,

6 tubes

,

7 tubes

,

8 tubes

,

9 tubes

,

10 tubes

Ενεργός Ουσία

,